Sanofi US News
WEB23 hours ago — Sanofi and Regeneron are committed to helping patients in the US who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay ® program. For more information, please call 1-844-DUPIXENT (1-844-387-4936) or visit www.DUPIXENT.com .
FDA signs off on Regeneron and Sanofi's Dupixent for COPD
WEB9 hours ago — The companies began testing Dupixent in COPD in 2018, taking a risk by going straight to phase 3. When interim results for the BOREAS trial were positive, Sanofi kicked off a second phase 3 trial ...
Sanofi/Regeneron’s Dupixent set to dominate COPD biologics …
WEB6 hours ago — After reviewing the data published from Sanofi/Regeneron’s two landmark Phase III studies (BOREAS and NOTUS), Dupixent was able to significantly reduce moderate or severe acute COPD ...
Blockbuster Dupixent wins FDA approval for COPD - STAT
WEB9 hours ago — Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD Drug is cleared for 300,000 U.S. patients with a form of the lung disease driven by eosinophils Manage alerts for this article
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
WEB9 hours ago — The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease commonly known as "smoker's lung", the companies said ...
Sanofi blockbuster drug wins clearance in US for lung disease
WEB7 hours ago — News Sports Autos Business Michigan Life + Home Entertainment Opinion Obituaries. Subscribe. ... Dupixent’s revenue for Sanofi may grow to €21 billion ($23.5 billion) annually by 2030 ...
Press Release: Dupixent approved in the US as the first-ever
WEBSep 27, 2013 — Sanofi and Regeneron are committed to helping patients in the US who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay ® program. For more information, please call 1-844-DUPIXENT (1-844-387-4936) or visit www.DUPIXENT.com .
Press Room - Sanofi US News
WEBMar 23, 2023 — The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase 3 trials, establishing that IL-4 and IL-13 are key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases.
Dupixent® - Pivotal Trial Results | Sanofi
WEBMar 23, 2006 — Dupixent® (dupilumab) shows promise as a groundbreaking biologic obtaining positive results in the pivotal trials. Learn more about these promising results.
FDA, after delay, clears Regeneron and Sanofi drug for COPD
WEB23 hours ago — European regulators approved Dupixent for COPD in July, but Regeneron and Sanofi have had to wait longer in the U.S., where the FDA requested additional efficacy data from the two trials. Over that time, a potential new competitor has emerged in GSK’s Nucala, which the FDA rejected in 2018 but earlier this month succeeded in a Phase 3 trial.
Skip to content